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ACKGROUND: Differential diagnosis 
between hemorrhagic and ischemic stroke, 
which determine how to treat the patients, was 
performed by CT-Scan. CT-Scan is not always available 
in all Indonesian health care facility. Other alternative 
using biochemical markers needed to be studied.
METHODS: In total of 44 stroke patients consist of 25 
ischemic and 19 hemorrhagic strokes according to CT-
Scan, participated in this study. S100B Protein, NSE, 
MBP and H-FABP concentration in the blood of each 
stroke patient was determined.
RESULTS: Among the biochemical markers used, 
only MBP at cut off point 0,712 ng/ml could be used 
for diagnosing hemorrhagic from ischemic stroke for 
serum samples obtained until 72 hours after onset 
of the stroke. If samples could be obtained within 
24 hours, S100B Protein and MBP could be used for 
diagnosing hemorrhagic from ischemic stroke. If both 
markers increased (S100B Protein > 7,55 pg/ml and 
MBP > 0,109 ng/ml) sensitivity and speciﬁcity would 
be 77.8% and 84.6% respectively.
CONCLUSIONS: MBP and S100B Protein are promising 
markers for differential diagnosis of hemorrhagic from 
ischemic stroke. Using serum samples obtained within 
24 hours after onset and multiple markers (MBP and 
S100B Protein) will improved diagnostic performance 
of the test.
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In Indonesia, stroke is the main cause of deaths in 
emergency room and major disability among middle-
age patients. The incidence rate of stroke is predicted 
higher in the future, along with increasing income and 
sedentary lifestyle.
Based on their pathology, stroke could be divided 
into hemorrhogic and ischemic stroke. Ischemic 
stroke need clot-dissolving agent, but the agent is a 
contraindication in hemorrhagic stroke (1,2).
Routine differential diagnosis of hemorrhagic 
from ischemic stroke is performed by Computed 
Tomography (CT) Scan and Magnetic Resonance 
Imaging (MRI). Both instruments not always available 
in all Indonesian health care facility (3,4).
Several neurospeciﬁc biomarkers for stroke 
have been studied. S100B Protein, NSE and MBP 
concentrations are elevated in the blood of stroke 
patients, and correlated signiﬁcantly with National 
Institutes of Health Stroke Scale (NIHSS) (5). Heart-Type 
Fatty Acid Binding Protein (H-FABP) concentration 
is elevated in the blood of infarct and stroke patients 
(6).
Patients and Methods
PATIENTS
In total of 44 stroke adult patients consist of 25 
ischemic and 19 hemorrhagic strokes according to CT-
Scan participated in this study. Written consent from 
subjects or patient’s family received before subjects 
were enrolled in this study.
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ASSAYS OF BIOCHEMICAL MARKERS
Serum S100B Protein, NSE and MBP concentrations 
were measured with Enzyme Linked Immuno 
Sorbent Assay kit from Syn X Pharma, Mississauga, 
CA. Serum H-FABP concentrations were measured 
with Enzyme Linked Immuno Sorbent Assay kit from 
Life Diagnostics, USA. Serum were separated from 
whole blood after centrifugation, and immediately 
kept at –20ºC until assays. All assays were performed 
according to manufacturers instruction.
For each run of serum S100B Protein, NSE and MBP, 
controls were included in the assays, and all results 
were within acceptable ranges. In our laboratory, the 
intraday imprecisions for all assays were lied between 
4.2% - 5.4%.
STATISTICAL ANALYSIS
All statistical calculations were performed using 
SPSS ver 11.5, SPSS Inc. Chicago. Parametric or non-
parametric calculations were chosen whichever 
appropriate based on the normality of the data. Chi-
Square analysis was used to determine association 
signiﬁcance of two nominal data. T-test or Mann-
Whitney U was used to compare means between two 
groups. ROC analysis was performed to determine 
cutoff point, and sensitivity and speciﬁcity at that point. 
Pearson or Spearman’s Rho was used to determine 
correlation signiﬁcance between two sets of data.
Results
All patients participated in this study are adults, men and women. There are not signiﬁcant different of gender 
proportion (p=0.901) and time to onset (0.232) between ischemic and hemorrhagic group.
Among four stroke biochemical markers: S100B Protein, NSE, MBP and H-FABP in which serum samples 
obtained up to 72 hours after onset, only MBP showed a signiﬁcant different in concentration between ischemic 
and hemorrhagic group, p=0.000.
The characteristics and serum biochemical marker concentrations of each group of all stroke patients are 
shown in table 1.
Table 1.  The characteristics and serum biochemical marker concentrations 
of each group of all stroke patients.
Variable Ischemic Group Hemorrhagic Group P-Value
N
Gender (%Female)
Time to onset (mean + SD), hours
NSE (mean + SD), ng/ml
S100B Protein (mean + SD), pg/ml
MBP (mean + SD), ng/ml
H-FABP (mean + SD), ng/ml
25
28.0
16,5 + 13,6
7,31+ 9,45
8,48+6,88
0,62+1,60
17,79+25,15
19
26.3
22,0 + 16,3
5,84+ 4,95
17,78+30,68
3,10+4,08
18,27+15,21
0.901
0.232
0.991
0.110
0.000**
0.139
** signiﬁcance at p<0.01
If patients in which serum samples obtained after 24 hours are excluded, then S100B Protein and MBP showed a 
signiﬁcant different in concentration between ischemic and hemorrhagic group, p=0.030 and 0.004 respectively.
Serum biochemical marker concentrations of each group of stroke patients which serum obtained within 24 
hours after onset are shown in table 2.
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Table 2. Serum biochemical marker concentrations of each group of stroke patients 
which serum obtained within 24 hours after onset
Variable Ischemic Group Hemorrhagic Group P-Value
N
NSE (mean + SD), ng/ml
S100B Protein (mean + SD), pg/ml
MBP (mean + SD), ng/ml
H-FABP (mean + SD), ng/ml
13
5,21 + 4,49
7,70 + 6,16
0,25 + 0,38
18,8 + 26,0
9
4,72 + 3,58
26,1 + 43,3
2,72 + 4,67
17,7 + 13,7
0.845
0.030*
0.004**
0.393
* signiﬁcance at p<0.05** signiﬁcance at p<0.01
Receiver Operating Characteristics (ROC) analysis showed that only area under curve of MBP (p=0.000) of up to 
72 hours obtained samples signiﬁcantly different from 0.5. But, if 24 hours samples obtained only, S100B Protein 
(p=0.030) and MBP (p=0.006) showed area under curved signiﬁcantly different from 0.5.
Area under curve (AUC) of S100B Protein and MBP using serum samples obtained up to 72 hours and 24 
hours are showed in Table 3.
Biomarker AUC P Value=
95% CI
Lower Upper
Up to 72 hours serum samples:
Protein S-100
MBP
0,642
0,822
0,110
0,000**
0,477
0,699
0,808
0,945
Within 24 hours serum samples:
Protein S-100
MBP
0,778
0,855
0,030*
0,006**
0,582
0,699
0,973
1,000
* signiﬁcance at p<0.05** signiﬁcance at p<0.01
Results showed that using serum samples obtained within 24 hours after onset, instead of up to 72 hours 
serum samples, improved performance of S100B Protein and MBP in differential diagnosis of hemorrhagic from 
ischemic stroke.
Further ROC analysis showed cutoff point, and sensitivity and speciﬁcity at the cutoff point. Table 4 showed 
cutoff point and its sensitivity and speciﬁcity for each marker in which the AUCs signiﬁcantly differ from 0.5.
Biomarker Cutoff Sensitivity (%) Speciﬁcity (%)
Up to 72 hours serum samples:
MBP 0,712 ng/ml 73,7 80,0
Within 24 hours serum samples:
Protein S-100
MBP
7,55 pg/ml
0,109 ng/ml
77,8
88,9
69,2
69,2
From Spearman’s Rho correlation analysis, a ll s troke b iomarkers showed signiﬁcant c orrelation each t o 
another (r ranges from 0.35 to 0.70, p<0.05), except between NSE and MBP (r=0.19, p=0.216).
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The m ain purpose of t his research i s limited to 
ﬁnd b iomarkers which a re c apable to d ifferentiate 
hemorrhagic from ischemic s troke. I n hemorrhagic 
stroke, patho-physiologically, there are more leucocytes 
especially Neutroﬁl and T-Cell inﬁltrate extravascular 
space of t he b rain c ompare w ith ischemic s troke. 
These inﬂammatory c ells a re r esponsible f or t he 
damage of neurons and/or glial cells through radical 
oxygen s pecies. M arkers of neurons and/or g lial 
cells damage w hich l eak i nto the circulation, c ould 
be detected in s erum o f the patients within hours 
after onset of the stroke. In the brain, glial cells are 50 
times m ore prominent t han neuron cells, s o the rate 
limiting increase of biomarkers in the circulation is the 
Discussion
number of leucocyte inﬁltrated. Markers of glial cells 
damage: S100B Protein and MBP would be higher in 
the circulation in hemorrhagic stroke c ompare w ith 
ischemic stroke, because leucocytes inﬁltration in the 
hemorrhagic stroke a re h igher t han ischemic s troke. 
On the other hand, markers of neuron cells damage: 
NSE and H-FABP only slightly and not signiﬁcantly 
increased i n hemorrhagic stroke c ompare w ith 
ischemic s troke, because the rate limiting increase 
of t he b iomarker i n the serum is t he number o f the 
damage c ells t heirsef. S chematic explanation of t he 
leak of stroke b iomarkers into c irculation after onset 
of the stroke is represented in ﬁgure 1 and 2.
Figure 1.  Schematic explanation of the leak of stroke biomarkers into circulation after onset of the ischemic stroke.
Figure 2.  Schematic explanation of the leak of stroke biomarkers into circulation after onset of the hemorrhagic stroke.
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Only markers of glials cells damage in this study could 
be used for differential diagnosis of hemorrhagic stroke 
from ischemic stroke. Increased MBP concentration, 
from serum obtained within 24 hours after onset or up 
to 72 hours after onsert, is associated with hemorrhagic 
stroke. Increased S100B Protein concentration is 
associated with hemorrhagic stroke only if serum could 
be obtained within 24 hours after onset of the stroke. 
After 24 hours, a rapid increased of S100B Protein in 
serum also occured in ischemic stroke. Figure 3 below 
ﬁgure out the rapid increased of S100B Protein after 
Ischemic Stroke (7)
Further analysis indicated that using markers of glial 
cells damage: S100B Protein and MBP simultaneously 
could decreased missclasiﬁcation from 5/22 (22.7%) 
to 4/22 (18.2%). Serum concentration of MBP equal 
or higher than 0,109 ng/ml and S100B Protein equal 
or higher than 7,55 pg/ml, both using serum obtained 
within 24 hours after onset of the stroke, are associated 
with hemorrhagic stroke.
Conclussion
MBP and S100B Protein are promising markers for 
differential diagnosis of hemorrhagic from ischemic 
stroke. Using serum samples obtained within 24 hours 
after onset and multiple markers (MBP and S100B 
Protein) will improve diagnostic performance of the 
test.
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